Chungpyesagan-tang is one of the most well-known traditional herbal formulations frequently used for treatment of @entity64 in Korea. Therefore, this study aims to assess the clinical safety and efficacy of chungpyesagan-tang on acute @entity385 . We recruited acute @entity385 subjects within 1 week after onset time. Then, we prescribed chungpyesagan-tang to an Oriental medical treatment group (OM-group) for 2 weeks and enrolled a Western medical treatment group (WM-group) which received only Western biomedical care as a control. In this study, the OM-group was composed of 75 subjects. However, 14 of them dropped out, as two had progressive @entity64 while 12 complained of @entity294 . Thus, 61 cases were included in the analysis and compared to the 76 cases of the WM-group. The improvement of OM-group was better than that of the WM-group according to the National Institute of Health @entity64 Scale (NIHSS), but not by the Modified Barthel Index (MBI). There were no definite abnormalities on labortory safety asessment. Therefore, we suggest that chungpyesagan-tang may have therapeutic effects, acting to reduce the severity of @entity64 and improving functional recovery without definite hepatic or @entity8 when given for the first 2 weeks after a @entity64 .

Safety and efficacy assessment of chungpyesagan-tang for acute XXXX .

@entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'acute stroke', 'Stroke'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke', 'cerebral infarction']
@entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']
